Skip to main content
A

Apex Biotechnology Corp. — Investor Relations & Filings

Ticker · 1733 TW Manufacturing
Open in API
Filings indexed 1,519 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country TW Taiwan
Listing TW 1733

About Apex Biotechnology Corp.

https://www.apexbio.com.tw

ApexBio is a developer and manufacturer of in-vitro diagnostic (IVD) solutions, specializing in biosensor technology. The company provides a comprehensive range of products, including self-monitoring blood glucose systems, multi-functional home health management devices, and point-of-care testing (POCT) equipment. Its core operations encompass the research, development, production, and global distribution of diagnostic tools designed for both home care and professional clinical environments. Recognized for its innovation in home-care blood glucose monitoring, the company leverages its technological foundation to offer integrated solutions for chronic disease management and professional clinical trials. ApexBio focuses on enhancing healthcare accessibility through reliable diagnostic innovation and a full range of IVD services.

Recent filings

Filing Released Lang Actions
公告本公司115年第一季財務報告提報董事會召開日期
Regulatory Filings
2026-04-30 Chinese
115年年報及股東會資料 — 2025_1733_20260522F04.pdf
Regulatory Filings
2026-04-28 Chinese
114年年報及股東會資料 — 2025_1733_20260522FE4.pdf
Annual Report Classification · 1% confidence The document is titled “ANNUAL REPORT 2025” and includes full sections typical of a comprehensive annual report: Letter to Shareholders, Corporate Governance details, full financial statements, management discussion, capital overview, operational highlights, and auditor information. It is not merely an announcement of publication but the full report itself. Therefore, it is classified as an Annual Report. FY 2025
2026-04-28 English
114年年報及股東會資料 — 2026_1733_20260522F17.pdf
Major Shareholding Notification Classification · 1% confidence The document is a Taiwan shareholding disclosure listing the top ten shareholders of the company as of 115/03/24, with their respective share counts, percentages, and inter-relationships. It is not an earnings, financial, or management report, nor is it a share issuance or buyback notice. This type of static top-ten shareholder table corresponds to a major shareholding notification (MRQ).
2026-04-28 Chinese
115年年報及股東會資料 — 2026_1733_20260522F01.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a full notice of the 115th annual shareholders’ meeting, including the meeting agenda, attendance sign-in card, proxy (委託書) form, instructions for voting and proxy solicitation points. It is sent to shareholders to inform them of meeting details and solicit their voting proxies. This corresponds to the definition of Proxy Solicitation & Information Statement (PSI). It is not the meeting results or a general report, but the pre-meeting proxy and information materials.
2026-04-17 Chinese
115年年報及股東會資料 — 2026_1733_20260522F02.pdf
AGM Information Classification · 1% confidence The document is a shareholder meeting handbook (‘議事手冊’) for the 115th Annual General Meeting, containing the meeting agenda, business and approval items, and appendices such as the operating report, audit reports, financial statements, and profit distribution – all materials prepared and distributed for the AGM. This matches the definition of AGM Information.
2026-04-17 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.